Personalized Medicine: Four Perspectives of Tailored Medicine
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
With the rapid advancement of scientific understanding in the medical field, everyday use of personalized medicine appears within our grasp. Unfortunately, there are still challenges to overcome. In many therapeutic areas, there remains a lack of deep understanding of disease processes and treatments. Additionally, drug development proceeds over a 5–10 year timeframe, during which time knowledge of treatments and potential predictive biomarkers continues to evolve. For successful development of a drug that is tailored to a biomarker-defined patient population and approved by regulators for such use, employment of appropriate statistical design and analysis methods is paramount. Consequently, statisticians can play a leading role in transforming the practice of medicine to a more personalized approach. We describe four perspectives in clinical development, together with examples of each, and discuss how to approach the problem of demonstrating that a treatment works better in a biomarker-defined subgroup of patients than in its complementary subgroup. The four perspectives provide a framework for design of clinical trials and subsequent analyses as they relate to clinical development. Subgroup identification is described as a controlled, disciplined search for finding the right patient for treatment and is distinguished from traditional, exploratory subgroup analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
The Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“Subgroup analysis has received ample negative or cautionary press owing to its misuse and misinterpretation (Cui et al. 2002; Lagakos 2006; Wang et al. 2007).”
BackgroundYusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014
The Challenge of Subgroup Analyses — Reporting without Distorting
Lagakos, S. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068070 · Cited by 504 · cited 1×
“Subgroup analysis has received ample negative or cautionary press owing to its misuse and misinterpretation (Cui et al. 2002; Lagakos 2006; Wang et al. 2007).”
BackgroundReduction of selection bias in genomewide studies by resampling
Sun, L., & Bull, S. B. (2005) · Genetic Epidemiology · doi:10.1002/gepi.20068 · Cited by 73 · cited 1×
“Using the out-of-bag samples to correct for bias in findings from in-bag samples is intuitive and has been demonstrated to be adequate in a number of situations (Sun and Bull 2005).”
Background
Cited by
Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials
Lipkovich, I., Dmitrienko, A., & B., R. (2017) · Statistics in Medicine · doi:10.1002/sim.7064 · Cited by 291
Digital Therapeutics: An Integral Component of Digital Innovation in Drug Development
Sverdlov, O., van Dam, J., Hannesdottir, K., & Thornton‐Wells, T. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1036 · Cited by 147
General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials
Dmitrienko, A., Muysers, C., Fritsch, A., & Lipkovich, I. (2016) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1092033 · Cited by 51
“Disciplined subgroup search The ultimate goal of disciplined subgroup search (Ruberg and Shen, 2015) is to determine the degree of true treatment heterogeneity across clinically relevant subgroups of patients.”
Background
Metadata
- Authors
- Ruberg, S. J., & Shen, L.
- Venue
- Statistics in Biopharmaceutical Research
- Publisher
- Informa UK Limited
- Published
- 2015-07-03
- Volume
- 7
- Issue
- 3
- Pages
- 214-229
- ISSN
- 1946-6315 (ISSN-L)
- OpenAlex
- W2121819178
- Cited by
- 64
- References
- 7
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized Medicine: Four Perspectives of Tailored Medicine. https://app.cochat.ai/papers/10.1080/19466315.2015.1059354
- The paper
- Ruberg, S. J., & Shen, L. (2015). Personalized Medicine: Four Perspectives of Tailored Medicine. Statistics in Biopharmaceutical Research. https://doi.org/10.1080/19466315.2015.1059354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.